Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00454389
Status:
UNKNOWN
Last Update Posted:
2011-07-27
First Post:
2007-03-28
Brief Title:
A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration
Sponsor:
NeoVista
Organization:
NeoVista
Study Overview
Official Title:
A Randomized Prospective Active Controlled Study of the Epi-Rad90 Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration
Status:
UNKNOWN
Status Verified Date:
2011-07
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CABERNET
Brief Summary:
The objective of the CABERNET Trial is to evaluate the safety and efficacy of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization CNV associated with wet age-related macular degeneration AMD The Epi-Rad90 Ophthalmic System treats neovascularization of retinal tissue by means of a focal directional delivery of radiation to the target tissues in the retina Using standard vitreoretinal surgical techniques the sealed radiation source is placed temporarily over the retinal lesion by means of a handheld medical device
Detailed Description:
Therapeutic advances in the arena of neovascular age-related macular degeneration AMD have provided multiple treatment options for the disease Radiotherapy has been studied in multiple clinical trials in the past with many studies showing a therapeutic benefit Treatment with radiotherapy and anti-VEGF compounds is a promising approach to treating AMD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None